Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest

This phase 2 trial is testing the targeted drug brigatinib in 118 people with ALK-positive non-small cell lung cancer that has spread or cannot be surgically removed. The main goal is to see how long the cancer stays under control before it progresses. Researchers are also studyi…

This study tested a combination of two drugs, fedratinib and nivolumab, in 30 adults with myelofibrosis whose disease no longer responded well to standard JAK-inhibitor treatment. The goal was to see if the combination could shrink the spleen, improve symptoms, or reduce the need…

This phase II trial tested a combination of thoracic radiotherapy and the immunotherapy drug durvalumab in 51 elderly or frail patients with stage III lung cancer who could not receive chemotherapy. The goal was to see if this approach is safe and can shrink tumors. The study foc…

This study tested whether giving the immunotherapy drug pembrolizumab before and after a standard tumor-destroying procedure (ablation) could improve outcomes for 30 people with early-stage liver cancer. The goal was to see if the combination could shrink tumors and delay recurre…

This study tested a drug called sacituzumab-govitecan in 58 people with advanced stomach cancer that had spread to other parts of the body. The drug targets a protein on cancer cells to deliver chemotherapy directly. The goal was to see if the drug could shrink tumors or slow the…

This completed registry study gathered information from 159 people with biliary tract cancers, including gallbladder cancer. The goal was to create a detailed database of patient experiences, treatments, and quality of life to help guide future research. No new drug or treatment …